Equities
  • Price (EUR)98.36
  • Today's Change-1.15 / -1.16%
  • Shares traded0.00
  • 1 Year change-7.69%
  • Beta1.6644
Data delayed at least 15 minutes, as of Nov 13 2019 15:25 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Revenue in USD (TTM)4.74bn
  • Net income in USD1.36bn
  • Incorporated1992
  • Employees2.66k
  • Location
    Alexion Pharmaceuticals Inc121 Seaport BlvdBOSTON 02210-2050United StatesUSA
  • Phone+1 (475) 230-2596
  • Fax+1 (203) 271-8198
  • Websitehttp://alexion.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALXN:NSQ since
announced
Transaction
value
Achillion Pharmaceuticals IncAnnounced16 Oct 201916 Oct 2019Announced2.21%1.23bn
Data delayed at least 15 minutes, as of Nov 13 2019 21:00 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.